Physician profile
Lamiere J Downing
NPI 1699750976
$174,975.04
in general payments reported to CMS, 2019-2025
5 companies · $120K in 2025
The $120K reported for 2025 was more than what 99% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,175 · 2023: $13K · 2024: $41K · 2025: $120K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $110K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $27K · Consulting Fee: $20K · Travel and Lodging: $14K · Food and Beverage: $2,726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $110,125.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $26,775.00 |
| Consulting Fee | $20,062.50 |
| Travel and Lodging | $14,111.31 |
| Food and Beverage | $2,726.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $119,163.91 | 2025 | Enroute Transcarotid Neuroprotection System, General - Therapies, Carotid Wallstent |
| Silk Road Medical, INC. | $54,112.23 | 2023-2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Medtronic Vascular, INC. | $1,174.83 | 2019 | |
| Medtronic, INC. | $502.33 | 2023-2025 | Heli-Fx Endoanchor System, Endurant Iis |
| Lifenet Health | $21.74 | 2025 | Theragenesis Wound Matrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lamiere Downing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.